Human malignant epithelial cell lines were analyzed for expression of platelet-derived growth factor (PDGF) genes. Of the 12 cell lines tested, 9, derived from breast, lung, gastric, and ovarian carcinomas, were found to express both PDGF-1 and PDGF-2 genes. The levels of both PDGF-1 and PDGF-2 transcripts were superinduced when these cells were treated with cycloheximide, an inhibitor of protein synthesis. These cells also released an activity that in studies with BALB-c/3T3 15-and 16-kD species under reducing conditions. In contrast, malignant cells of ovarian origin produced 14-16-kD PDGF-like proteins that were unchanged in mobility after reduction. As PDGF receptors were not detected on these malignant epithelial cells, the production of PDGF-like proteins may affect other cells in the microenvironment by paracrine mechanisms and may contribute to excessive cell proliferation, inflammatory reactions, and connective tissue remodeling seen in certain carcinomas.
Introduction
Platelet-derived growth factor (PDGF),' a potent mitogen for cells of mesenchymal origin, is released from human blood platelets upon their degranulation (for review, see references 1 and 2) . It consists of two polypeptide chains, PDGF-l (or 1. Abbreviations used in this paper: CHX, cycloheximide; CM, cellconditioned media; HTLV, human T cell lymphotropic virus; PDGF, platelet-derived growth factor. bonds and encoded by two different genes located on chromosomes 7 and 22, respectively (3) (4) (5) . The PDGF-l and PDGF-2 genes code for precursor polypeptides whose predicted amino acid sequences have an overall 40% homology, while there is a 56% homology between the two mature PDGF chains (5) . The PDGF-2 chain is very similar structurally, antigenically, and functionally to the p28tm transforming protein of the simian sarcoma virus (6) . Whereas human PDGF is believed to be a heterodimer (7, 8) , the PDGF-like protein produced by the human osteosarcoma U20S cell line is a homodimer of PDGF-I chains (9) . The 30-32-kD authentic PDGF protein has mitogenic and chemotactic activity (1, 2) , is a potent vasoconstrictor (10) , and stimulates synthesis of both matrix components (11) and enzymes that degrade this matrix (12, 13) .
PDGF-like proteins have been detected in endothelial cells (14, 15) , vascular smooth muscle cells (16) , and cytotrophoblasts (17) . However, human plasma contains undetectable levels of PDGF. The ability of target cells to be activated by PDGF thus depends on local secretion and thereby on the anatomical location of cells producing PDGF. PDGF-like proteins also have been detected in several human malignant cell lines of mesenchymal origin (18) (19) (20) that also possess PDGF receptors (19) . This finding has raised the possibility that autocrine stimulation ofthese cells could contribute to the transformed state and the development of automitogenic cell populations (19) .
In this communication, we report that PDGF-1 and PDGF-2 mRNAs are expressed in human malignant epithelial cells of breast, ovary, lung, and gastric origin. Malignant breast, lung, and gastric cells produce 30-32-kD PDGF-like proteins that are similar in molecular weight to authentic PDGF and PDGF-like proteins detected in transformed human cell lines of mesenchymal origin. In contrast, malignant cells of ovarian origin produce 14-16-kD PDGF-like proteins that are similar in molecular weight to those detected in activated human macrophages. Furthermore, we demonstrate that the PDGF-like species secreted by malignant epithelial cells are biologically active.
As PDGF receptors were undetectable in malignant epithelial cells, these results suggest that PDGF-like proteins produced by these cells act through a paracrine mechanism. This mechanism may represent a way whereby malignant epithelial cells interact with and modulate their microenvironment. (24) .
PDGF and PDGF antibodies. PDGF was purified from human platelets and labeled with 25I by the chloramine T method, using lodobeads (Pierce Chemical Co., Rockford, IL), to a specific activity of 15,000-20,000 cmp/ng as described (25) . A rabbit antibody to PDGF was prepared in our laboratory as described (25) . Assay for mitogenic activity. Growth-promoting activity of cellconditioned media (CM) was tested as described (25) . Briefly, 10 25 -fold excess of unlabeled PDGF. Cell-associated radioactivity was measured as-described above. To assay for the presence of occupied PDGF receptors, the experiments were repeated as described (25) after the cells were preincubated with the polyanion suramin (1 mM), a drug known to dissociate PDGF from high-affinity binding sites (26, 27) .
Results
Malignant epithelial cells express PDGF-J and sis/PDGF-2 mRNAs. RNA prepared from the 12 malignant epithelial cell lines was analyzed for the presence of PDGF-1-and PDGF-2-related transcripts (Figs. 1 and 2). PDGF-l mRNA was detected in each of these cell lines. The sizes of these PDGF-1 transcripts, (2.8, 2.3, and 1.9 kb), were similar to those reported for malignant human cells (5) . A 4.2-kb PDGF-2 (c-sis) transcript was also detected in breast (three of three), lung (two of two), gastric (one of one), and ovarian (three of four) cells, lyzed for PDGF-1 and PDGF-2 transcripts using the PDGF-I and PDGF-2 cDNA probes. One cell line (MAC) was also exposed to 10 ug/ml CHX for I h before RNA extraction.
(ARM, Fig. 2 ) and in the MCF-7 breast cells after polyA selection (data not shown). The levels of both PDGF-1 and PDGF-2 transcripts increased when gastric or ovarian cells were treated with cycloheximide (CHX), an inhibitor of protein synthesis (Figs. 1 and 2); similar results were found when breast-or lung-derived cells were exposed to CHX (data not shown). These findings suggested that the synthesis of a labile protein was responsible for regulating levels of both Table I , detectable amounts of mitogenic activity were found in all 10 of the tested CM. Heat treatment (1000C for 10 min) of the CM did not affect mitogenic activity, whereas this activity decreased after reduction ofCM with mercaptoethanol or after preincubation of the CM with 100 ng/ml anti-PDGF IgG (Table I) . Altogether, these results suggested that a significant proportion of the mitogenic activity detected in the CM of these carcinoma cells was related to the presence ofPDGF-like proteins.
PDGF receptor competing activity. CM derived from five epithelial cell lines (one lung, one gastric, one breast, and two ovarian lines) were analyzed for their ability to compete for '25I-PDGF binding to the PDGF receptor on 3T3 fibroblasts.
As shown in Fig. 6 , all CM from the tested lines inhibited binding of '25I-PDGF to fibroblasts in a dose-dependent manner. On the basis of radiocompetition studies using purified PDGF, we estimate the concentration of PDGF in the unconcentrated CM of these malignant epithelial cells to be 1-6 ng PDGF/ml.
Epithelial cells do not display PDGF receptors. Specific '25I-PDGF binding to malignant epithelial cell lines was compared with the binding detected in 3T3 fibroblasts. When incubated with 1 ng/ml I25I-PDGF, 11% ofthe radioactivity was found to bind to 3T3 cells (Table II) . In contrast, only 1.1-1.9% of the labeled PDGF bound to six of the malignant epithelial cells. This low level of binding was considered nonspecific since it did not decrease after incubation of these cells with an excess of cold PDGF and was comparable to the amount ofbinding obtained after incubation of 3T3 cells with an excess of cold PDGF (50 ng/ml). Similar low levels of l25I-PDGF binding were obtained when three cell lines (BT-20, A549, and KATO III) were pretreated with suramin. This drug dissociates PDGF bound to cell membranes and thus unmasks PDGF receptors (26, 27) . The absence of a significant increase in '251-PDGF binding after suramin treatment provided further evidence that these malignant epithelial cells lack detectable PDGF receptors. Finally, we were unable to detect mRNA for the PDGF receptor gene in 10 epithelial cell lines, whereas these transcripts were present in 2 different clones of a mouse fibroblast cell line (Fig. 7) .
Discussion
The present results demonstrate that PDGF-I and sis/PDGF-2 mRNAs are expressed in human malignant cells derived from breast, ovarian, lung, and gastric epithelium. A previous study demonstrated the presence of both transcripts in human sarcoma cell lines (5), whereas subsequent work detected only PDGF-l mRNA in three human melanoma cell lines (29) . The detection of PDGF-2 transcripts in malignant epithelial cells, however, is in contrast to the findings ofa previous study (30) . Although the basis for this discrepancy is unclear, our results clearly demonstrate that expression of both the PDGF-I and PDGF-2 genes is widespread among human carcinoma cell lines. Our findings also suggest that the expression of both genes is regulated by protein(s) with a short half-life. Similar results were obtained in human macrophages exposed to CHX (29a) suggesting that both genes were under similar control(s) in cells of mesenchymal or epithelial origin.
We also demonstrate that human malignant epithelial cells of diverse tissue origin produce biologically active PDGF-like proteins. These proteins were characterized as being PDGFlike on the basis of antigenic similarities with authentic PDGF and on their ability to compete with '251I-PDGF in a dose-dependent manner for high-affinity binding receptors. The estimated concentration of PDGF-like material in the conditioned media of these epithelial cells ranges from 1 to 6 ng/ml.
The secreted PDGF-like species differ in molecular weight according to tissue origin of the epithelial tumor cells. PDGF Each point represents the mean of triplicate samples of two experiments (SD < 5%, n = 6). By extrapolation to the standard curve the estimated amount of PDGF-like material in unconcentrated CM was estimated to be 1-6 ng/ml. *, standard curve (competing activity of unlabeled PDGF); A, DUN (ovary); a, KATO III (gastric); o, A549 (lung); A, ARM (ovary); o, ZR75-1 (breast). a 3 1-kD PDGF-like protein with mitogenic activity has been detected in two human breast carcinoma cell lines (32) (33) (34) . In contrast, the major PDGF-like species detectable in tumor cells of ovarian origin had molecular masses of 14-16 kD. Furthermore, biologically active PDGF-like proteins secreted by macrophages have molecular masses of 12-13.5 kD, which are unchanged after reduction (35). Although the low-molecular weight PDGF-like species detected in ovarian cells and in macrophages share similar characteristics, whether they are in fact identical proteins remains unclear. Further, high-molecular weight PDGF-related proteins of 45-185 kD were also detected on reducing gels. Similar proteins have been observed in human glioblastoma, fibrosarcoma, and HTLV-infected T cell lines (20, 31). However, these proteins are not mitogenic for fibroblasts. We have recently demonstrated that complexes of PDGF and the complement component 3 (C3) are coprecipitated during the immunoprecipitation reaction (Pantazis, P., (26, 27 ) PDGF producer. Use of this drug in our study failed to reveal the presence of occupied PDGF recep- tors. The lack of PDGF receptors in epithelial cells was consistent with the absence of PDGF receptor mRNA in these cells. This finding is in agreement with the lack of mitogenic response of carcinoma cells to PDGF (38) . None of the six human malignant epithelial cell lines derived from lung, thyroid, epidermis, and neuroblastoma studied previously had PDGF receptors (39) . The presence of high-affinity cell surface receptors for PDGF thus seems to be limited to mesenchymederived cells. Further, it has been recently reported that there is more than one PDGF receptor phenotype (40) . The three different PDGF protein isoforms thus should be tested in binding studies to definitively evaluate the presence ofPDGF receptors on these cells. PDGF may stimulate growth by an autocrine mechanism in mesenchyme-derived cells (19) . In contrast, PDGF apparently acts in a paracrine fashion in epithelial cells. PDGF is a mitogenic factor for fibroblasts and smooth muscle cells, and is a potent chemotactic factor for neutrophils (41) , monocytes (42) , and smooth muscle cells and fibroblasts (1, 2) . The fibrosis and inflammatory reactions seen in tumors of epithelial origin thus may be mediated by PDGF-like molecules secreted by the malignant epithelial cells. Alternatively, many of the biological effects of PDGF-like proteins secreted by the epithelial cells may be mediated through the activation of fibroblasts. In this regard, PDGF has been shown to induce fibroblasts to secrete growth factors such as somatomedin C, a potent fibroblast growth factor (43) . Additionally, the fibroblast is a source of the colony-stimulating factor, CSF-1 (44) , which is essential for the growth and differentiation of monocytic cells. The fibrosis, neovascularization, and inflammation seen in epithelial tumors thus may be either related to the direct effect of PDGF on specific target cells or secondary to the release of diverse growth factors by the PDGF activated fibroblasts. Since our study was performed on cultured cells derived from tumors and not on primary tissues, further studies are needed to determine: (a) if PDGF production by malignant epithelial cells occurs in vivo, (b) ifPDGF secretion is a physiological event in normal epithelial cells, and (c) if PDGF production can be regulated in these cells by specific ligand-receptor interactions.
